May 22, 2017 Issue

The AARS online Hot Topics Newsletter is an exclusive AARS member benefit!

This is a semi-monthly compilation of peer-review literature and online updates in acne and rosacea covering industry press, new medical research and what patients and your peers are talking about in patient counseling tips.

Access Hot Topics Newsletter

You don't need to spend countless hours perusing your typical online sources when you have this! Stay informed today by becoming an AARS member and receiving the Hot Topics!

Industry News

  • Cosmetic companies have started developing and selling products designed to harness the skin microbiome to help treat a range of skin conditions from acne to eczema. The cover story in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, scopes out the scene.
  • Foamix Pharmaceutical recently announced that based on the results of its first two phase 3 trials, it will conduct a third U.S. phase 3 trial of FMX101 to treat patients with moderate-to-severe acne. The trial is slated to begin mid-year, and if results are positive, the trial could form the basis of a new drug application (NDA) for FMX101 (minocycline foam 4%), which the company plans to submit in the second half of 2018, according to a news release from Foamix.
  • BioPharmX announced that BPX-01 showed efficacy in both 1% and 2% doses in treating moderate-to-severe acne in children and adults.

New Medical Research

  • A study to evaluate the efficacy and safety of DL-PDT in moderate to severe acne and to compare outcomes with those of laser-assisted daylight photodynamic therapy found that DL-PDT with MAL shows clinically good responses to inflammatory lesions and is well tolerated in patients with moderate to severe acne.
  • A new evidence-based study on the skin-care effects of loquat (Eriobotrya japonica) leaves showed that twelve compounds exhibited anti-acne effect; ursolic acid (1), maslinic acid (7), corosolic acid (8) and euscaphic acid (12) showed highest activities against P. acnes.
  • An observational cohort study performed in 111 patients with adult acne (AA) (> 25 y.o.) in 2015-2016 concluded that lifestyle change-related stress, sensitive skin, discontinuation of oral contraceptives and using full-coverage foundations increase severity of AA.
  • A new case report highlights  a male long-term survivor of T13, currently 15 years of age, with a several-year history of extensive acne conglobata (AC) with abscesses on the face and neck. Immunoglobulin replacement therapy elevated serum IgM levels to the normal range and reduced the severity of AC.
  • Results of a recent investigation demonstrated that selective modulation of proliferator-activated receptor gamma (PPARγ) activity is likely to represent a therapeutic strategy for the treatment of acne.
  • A new clinical trial study to evaluate the effect of H. pylori standard eradication protocol on the rosacea clinical course concluded that H. pylori eradication leads to improvement of rosacea.
  • A new study report describes a Dowling-Degos disease (DDD) subphenotype in PSENEN mutation carriers that is associated with increased susceptibility to acne inversa (AI).
  • A case report of a 16-year-old female presenting with symptoms of tremors, lack of focus, sleeplessness, emotional liability, bulging eyes, loose stools, heat intolerance, and missed menstrual periods that manifested shortly after the patient finished a course of oral isotretinoin treatment for acne suggests that isotretinoin may play a role in triggering autoimmunity in genetically susceptible individuals.
  • Acne RA-1,2, a novel dermato-cosmetic product which contains selective photofilters and active ingredients against the multifactorial pathophysiology of acne, was shown to be well tolerated and effective at reducing comedones and sebum production and improving epidermal barrier function in acne patients.

Clinical Reviews

  • A systematic literature review of clinical risk factors for acne scars, a Delphi-like survey of dermatological experts in acne and secondary data analysis were conducted in order to produce an evidence-based risk assessment tool. Investigators found that a potential benefit of this tool is to encourage those at risk to self-identify and to seek active intervention of their acne.
  • A recent Letter to the Editor challenges the findings of Tan, et al., citing that ROSCO's claimed 'phenotypic approach' seems to be simply the elimination of these phenotypic subtypes.
  • Results of a 4-year retrospective study evaluating 291.5 patient-years of spironolactone for the treatment of acne showed that 86% of patients improved on spironolactone therapy, suggesting that spironolactone should be considered for postadolescent acne.
  • A recently published article details how regression analysis found rosacea (OR = 1.40, 95% CI 1.13-1.72) and telangiectasia (OR = 1.25, 95% CI 1.10-1.41) to be significantly associated with psoriasis.
  • Based on a literature search of skin needling as a treatment for acne scarring found moderate evidence to suggest that skin needling is beneficial and safe for the treatment of acne scarring.
  • A new article discusses the role of probiotics in the development of the immune system, the treatment of acne and rosacea, and protection against aging and photodamage.
  • In a recent article, investigators describe the different sampling strategies that have been adopted for qualitative and quantitative study of P acnes within intact hair follicles of the skin and discuss the strengths and weaknesses of such methodologies for investigating the role of P acnes in the development of acne.
  • A systematic search of the PubMed Database concluded that combined oral contraceptive medications and spironolactone as adjuvant and monotherapies are safe and effective to treat women with adult acne.
  • A survey of 116 US dermatologists about their knowledge, comfort, and prescribing practices pertaining to the use of OCPs indicated that many dermatologists believe the benefits of increased treatment efficacy may outweigh the risks.
  • A study to examine the evidence supporting the dermatological use of seaweed, witch hazel, bearberry, and mayapple found that seaweed has potential clinical use in the treatment of acne and wrinkles and may be incorporated into biofunctional textiles.

Patient Counseling / Communication

  • An interview with Dr. Anjali Mahto, Consultant Dermatologist & British Skin Foundation spokesperson, explored the impact acne has on the self-confidence of teenagers.
  • Appropriate skin care recommendations for patients with acne and rosacea, including an integrated management approach of patient education, selection of therapeutic agents, and initiation of an appropriate skin care regime, are discussed in a recent article.
  • Results of a prospective study of 127 patients suffering from moderate to severe form of acne showed no higher risk of depression and anxiety within the patients with acne treated with oral isotretinoin. Improvement of quality of life after the treatment of acne with oral isotretinoin was confirmed.
  • While the overall pathogenesis and treatments for acne in women of color are similar to Caucasian men and women, individuals with darker skin types present more frequently with dyschromias from acne, which can be difficult to manage. Understanding the differences in the basic science of skin and hair is imperative in addressing the unique needs of women of color seeking dermatologic care.
  • A new article provides evidence-based clinical updates to clinicians, specifically general practitioners (GPs), to assist with their everyday practice, and effective assessment and treatment of rosacea.
  • Results from a study to evaluate different aspects of rosacea that could contribute to feelings of stigmatization suggest that stigmatization is important in the daily lives of those with rosacea and should be taken into consideration in the management of these patients.